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Abstract: We present a robust protocol based on iterations of
free energy perturbation (FEP) calculations, chemical syn-
thesis, biophysical mapping and X-ray crystallography to
reveal the binding mode of an antagonist series to the A2A
adenosine receptor (AR). Eight A2AAR binding site mutations
from biophysical mapping experiments were initially analyzed
with sidechain FEP simulations, performed on alternate
binding modes. The results distinctively supported one binding
mode, which was subsequently used to design new chromone
derivatives. Their affinities for the A2AAR were experimentally
determined and investigated through a cycle of ligand-FEP
calculations, validating the binding orientation of the different
chemical substituents proposed. Subsequent X-ray crystallog-
raphy of the A2AAR with a low and a high affinity chromone
derivative confirmed the predicted binding orientation. The
new molecules and structures here reported were driven by free
energy calculations, and provide new insights on antagonist
binding to the A2AAR, an emerging target in immuno-
oncology.
Introduction
Computational estimation of shifts in binding free energy,
associated with ligand modifications or point mutations in the
receptor macromolecule, can provide the missing link be-
tween the structure of a protein-ligand complex and a panel of
experimental binding affinities. Rigorous free energy pertur-
bation (FEP) methods have been used for decades to
understand the structure-affinity relationships (SAR) around
a given chemical scaffold, and recent advances now allow the
use of this technique routinely in ligand design projects.[1] The
same methodology can be used to analyze this problem from
a complementary perspective, that is to estimate the gain or
loss in binding free energy from site-directed mutagenesis
(SDM) data. The idea of in silico mutagenesis, initially
introduced almost three decades ago by Kollman to study the
binding and catalysis of subtilisin,[2] was recently implemented
in computational pipelines that pursue a systematic character-
ization of the effect on point mutations on for example,
ligand-binding or protein stability.[3–5] The combination of
both ligand and residue FEP simulations can provide a full
energetic landscape of the molecular interactions governing
protein-ligand binding, which underlies the design of two
complementary protocols in our lab, namely QligFEP[6] and
QresFEP,[3] integrated in the molecular dynamics (MD)
software package Q.[7, 8]
One area where this approach is particularly promising is
the design of ligands for G-protein-coupled receptors
(GPCRs), a superfamily of seven-transmembrane (7TM)
cellular receptors[9] that mediate the therapeutic effects of
about 30 % of all marketed drugs.[10] There is a large amount
of SAR and SDM data available for these receptors, which
can be combined with the increasing growth of structural
knowledge of many GPCR targets. The first integrated
approach of ligand and residue FEP simulations was pub-
lished by Boukharta et al. to characterize antagonist binding
to the Y1 neuropeptide receptor,
[11] which we later expanded
to other GPCR families, including the related neuropeptide
receptor Y2,
[12] the orphan receptor GPR139[13] and several
members of the family of adenosine receptors.[14–16] Among
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the latter, the adenosine A2A receptor (A2AAR) was one of
the first GPCRs to be crystallized[17] and today stands out as
one of the better characterized GPCRs from a structural
perspective. Several structures of the inactive and active
forms of the receptor have been solved within the last
decade, and the integration of the available experimental data
has strongly aided ligand design programs for this recep-
tor.[18, 19]
Many A2AAR antagonists have been developed targeting
a number of pathologies,[20–22] including recent clinical candi-
dates in immuno-oncology. A number of these antagonists
have been co-crystallized with the A2AAR, providing unique
structural information which, in combination with the exten-
sive SDM data available,[23] allow envisaging ligand binding
mechanisms and structure-based drug design (SBDD) pro-
grams of antagonist molecules.[18] However, suboptimal
properties of traditional scaffolds, such as poor pharmacoki-
netics and low selectivity profiles, motivate the search of
novel chemical entities as A2AAR antagonists,
[24] frequently
through high throughput screening (HTS) campaigns. In these
cases, it is not common to obtain a crystal structure of the
receptor-ligand complex, which can hamper further hit to lead
optimization. Instead, approximate binding modes are often
inferred from the experimental data extracted from SAR of
ligand series and SDM data,[23] which can be complemented
by computational models of the protein-ligand complex.[25]
Biophysical Mapping (BPM), is an integrated approach
that has been used with success in antagonist design programs
on the A2AAR and other GPCRs.
[27–30] Here, the binding
affinity of a ligand series is evaluated via surface plasmon
resonance (SPR) on a panel of mutant receptors, each bearing
a single-point mutation within the putative binding site.[27]
The resulting matrix of binding affinity shifts from wild type
(WT) affinities combined with SAR data and mapped to
a receptor-ligand model provide further insights in the
determinants of binding of the scaffold. The first application
of this technique was based around the co-crystallized A2AAR
antagonist ZM241385 in combination with 8 receptor mutants
(see Figure 1A).[22] These mutations involve residues in direct
contact with the ligand, such as N2536.55, L853.33, M1775.38,
N1815.42 and I662.64 (Ballesteros Weinstein numbering[31] in
superscript), as well as residues not directly in contact with
the ligand, namely S2777.42, Y2717.36 and L167EL2 (see Fig-
ure 1). This approach was extended for 1,2,4-triazines as
A2AAR antagonists,
[32] and the binding mode was later
confirmed by X-ray crystallography (see Figure 1B).[29] In
the same HTS campaign, a series of chromones were
identified as a novel family of A2AAR antagonists,
[32] and
consecutively optimized to yield the potent and selective
Chromone 14 (see Figure 2).[30] At that point, the lead-
optimization program was successful in improving the affinity
of the initial HTS hit, while not focusing on pharmacokinetic
optimization (i.e., the most potent compound Chromone 14
contains a metabolically unstable ester group). Interestingly,
this structure-based optimization was guided by the interpre-
tation of the BPM data and a computational model of the
complex generated by docking. This led to the proposal of two
putative binding modes compatible with the BPM data. Even
if the SAR of the generated series seemed to favor one of
them, the question remained open due to the lack of an X-ray
structure with any of these compounds in the original
study.[30,32]
Here, we initially examine the SPR data available for
these A2AAR antagonist families through a recently devel-
oped in silico mutagenesis tool based on free energy
perturbation (FEP) simulations.[11, 14, 15] The results pointed
to a unified binding mode of the chromone series, which is
here used as a basis for the design, synthesis and pharmaco-
logical evaluation of an extended series of compounds aimed
to further explain the underlying SAR of chromones as
A2AAR antagonists. Finally, experimental structures of
two chromone-A2AAR complexes were solved which con-
firmed the binding mode hypothesis from the computational
studies.
Results and Discussion
Free Energy Perturbation Calculations on Existing BPM Data
The BPM data obtained for the three chemotypes of
A2AAR antagonists were collected from reference [27], and
relative binding free energy changes between mutant and WT
receptor were calculated from Ki values (see Table 1,
DDGexpbind). Thereafter, relative binding free energies for each
ligand were calculated based on 3D models of the receptor-
ligand complexes (DDGcalcbind, Table 1). In the case of
ZM241385, the model was directly extracted from the high-
resolution structure with the A2AAR (see Figure 1), and the
curated receptor model (see Supporting Information, Meth-
ods) was used throughout this work. The results show
excellent agreement with the experimental data, with a mean
absolute error (MAE) of 0.41 kcalmol@1 and a correlation
coefficient of R2 = 0.94 (Table 1). Next, the same set of BPM
mutations was analyzed for triazine 4g. In this case, the
starting configuration of the complex was obtained by
Figure 1. Binding mode and chemical structures of antagonists
ZM241385 (A, crystal structure 4EIY[26]) and triazine 4b (B). The
experimental pose of the triazine (cyan) was superimposed on the
same crystal structure of the receptor shown in panel A (ribbons).
Both compounds had been characterized by BPM (residues labelled
and depicted in gray sticks). Receptor-ligand hydrogen bonds are
depicted as magenta lines.
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aligning the triazine 4g-A2AAR complex (3UZA) to the
curated model described before, retaining only the coordi-
nates of the ligand (Figure 1B).[33] The calculated free
energies (DDGcalcbind, Table 1) were in general good agreement
with the experimental data (MAE = 0.94 kcal mol@1; R2 =
0.66). In contrast to the previous case, two mutations
(Met1775.38 and Asn1815.42) show qualitative discrepancy with
the experimental data for this ligand. Subsequent analysis of
the MD trajectories suggests that this is likely due to
a suboptimal representation of the (water mediated) H-bond
network upon mutation, which has previously been recog-
nized as a challenging factor for this particular scaffold.[34,35]
Once the QresFEP protocol was validated to reproduce
the BPM data on experimentally known structures, we moved
on to the chromone scaffold, for which there is analogous
BPM data, but no crystal structure available. Here, two
reasonable binding modes were generated by molecular
docking of Chromone 14. The two poses, denoted as A and
B (see Figure 2), form at least one hydrogen bond with
Asn2536.55 (a highly conserved interaction in AR ligand
recognition)[23] and are related by a symmetry axis along the
bicyclic core of the chromone scaffold. According to the
docking score function used, both poses were energetically
equivalent (@9.30 vs. @9.17 for pose A and B respectively)
making it difficult at this point to discern the correct one, in
line with the previous binding hypothesis by Andrews
et al.[30, 32]
In pose A (Figure 2A), Asn2536.55 forms an H-bond with
the nitrogen in the 4-methylthiazole group, leaving the
carbonyl group potentially exposed to the internal water
network stabilized by residues in TM7, as observed in the
A2AAR crystal structure with ZM241385
[26] (see Supporting
Information, Figure S1). Conversely, in pose B (Figure 2B)
this carbonyl forms an additional hydrogen bond with
N2536.55. We hypothesized that in principle, the symmetry
axis would allow exchanging substituents at R6 and R7
between the binding poses, something that we would explore
later in this work (see below).
Our strategy to select the most reliable binding mode was
to compute the effect on ligand binding of the 8 mutations
from the BPM panel[27] for each pose, and compare the results
with the experimental values. The results (Figure 2C, Table 1
and Supporting Information, Table S1) highlight pose A as
the binding mode with the best correlation to experimental
data. A MAE of 0.50 kcalmol@1 was observed for this pose,
which is comparable to the results obtained for the co-
crystallized antagonist ZM241385. In addition, the correlation
coefficient of R2 = 0.74 falls between those observed for
ZM241385 and triazine 4g. Conversely, the corresponding
values calculated on pose B are much higher (MAE =
1.53 kcal mol@1) and the correlation is completely lost (R2 =
0.03). Additionally, the computed loss of binding affinity upon
the N2536.55A mutation is closer to experiment in pose A than
in pose B, indicating that the additional H-bond between
Asn2536.55 and the carbonyl in pose B would not contribute to
more favorable binding free energies. From the MD simu-
lations, we further observed that the binding modes are not
related by a symmetry axis as initially hypothesized, and the
substituents at positions R6 and R7 are exploring different
positions in the binding site, making them no longer readily
interchangeable.
Figure 2. Putative binding modes A (green) and B (magenta) of
Chromone 14 to the A2AAR (H-bonds in magenta). C) Experimental
and calculated changes in binding free energies for each mutation in
the BPM. The error bars correspond to the s.e.m. of the replica
calculations for the calculated values, or are adjusted to the reported
value of 0.1 pKD unit in the case of experimental data.
[27]
Table 1: Comparison between experimental and calculated relative
binding free energies (DDGbind in kcal mol
@1) for A2AAR mutants.






I66A2.64 0.14 0.83:0.34 0.41 1.94:0.34
L85A3.33 2.45 3.30:0.41 1.09 1.65:0.37
L167A5.28 0.00 0.60:0.31 @0.14 @0.39:0.36
M177A5.38 0.14 @0.09:0.44 @0.27 1.66:0.49
N181A5.42 1.23 1.47:0.57 0.82 @0.63:0.55
N253A6.55 +5.86[c] 5.81:0.57 +4.36[c] 5.64:0.56
Y271A7.36 1.09 0.84:0.74 0.41 @0.1:0.68
[a] Data for the mutant receptor constructs reported in reference [27].
[b] Experimental relative binding free energies were calculated from KD




with experimental errors in all
cases reported as approximately 0.1 pKD unit, that is, less than
0.1 kcalmol@1.[27] [c] Binding affinity of the ligand to the (mutant)
receptor was lower than the experimental threshold (pKD<5 in all
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Design, Synthesis and Pharmacological Evaluation of Chromone
Derivatives
On the basis of the binding mode hypothesis assessed by
the FEP calculations, we designed a small collection of
chromone derivatives (Scheme 1), aiming to systematically
explore two different variables on A2AAR affinity: methyl-
ation at position 2 (series 5) and the aforementioned effect of
switching the oxygenated function (@OH or@OCOMe) from
the original position 7 (series 4) to position 6 (series 8),
swapping the alkyl substitution (Pr/H) accordingly. A collec-
tion of 11 molecules was prepared as depicted in synthetic
Scheme 1. Structure and synthetic pathways employed to assembly chromones 4, 5 and 8.
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Scheme 1. Briefly, the key 2-hydroxyphenyl ketones 3 were
obtained by either the Hoesch method[30] or Claisen con-
densation,[36] employing phenols 1 or esters 6 and thiazole
derivatives 2a and 2 b as reactive precursors, respectively.
Treatment of ketones 3 with orthoesters (formate or acetate)
enabled the efficient chromone core formation,[37] thus
defining the substituent pattern at position 2 (H or Me).
Finally, the required acetates were prepared by reaction of the
corresponding phenols with acetyl chloride. The full synthetic
methodology is provided in the Supporting Information.
The affinity of these compounds for the WT A2AAR was
then evaluated with the same SPR assay used to generate the
BPM data, using the A2AAR-STAR2 construct (see Support-
ing Information, Methods).[27] The data confirmed that
methylation at position 2 (compounds 5a–d) is generally
unfavorable for binding, compared to the parent series
(compounds 4a–d). This is in agreement with previous work
by Andrews et al.,[30] where methylation of the low affinity
compound 4a (corresponding to chromone 8 as reported by
Andrews et al. ,[30] with pKi = 5.7) resulted in a relative
decrease in affinity of 0.6 log units (Chromone 12, pKi =
5.1). We observe a similar difference for this pair of
compounds (Table 2, DpKD = 0.85), while this effect is
amplified in the case of the high affinity precursor (see 4d
as compared to 5d, DpKD = 2.7). More surprising was the
observation of a similar effect when the substituents between
R6 and R7 are swapped (compounds 8a–d), which again was
most pronounced for the high affinity compound 4d (see
Table 2), with a drop of affinity of 2.7 log units for the
corresponding methylated derivative 8d.
Computational Evaluation of the Proposed Binding Modes
From the pharmacological data on the expanded series of
chromones and the initial MD simulations, it appears that the
two binding poses differ more than just purely on the rotation
axis of the chromone scaffold.
The following step was then to investigate whether all
compounds in the series would adopt the preferred binding
mode A, or if binding mode B is accessible by some of the
compounds, depending on the pattern of substitutions. Such
a hypothesis was experimentally observed for caffeine, which
in contrast to other xanthine derivatives presents a dual
binding mode to the A2AAR (see Figure 3A). Indeed, an
isoenergetic dual binding mode for caffeine was previously
hypothesized on the basis of free energy calculations,[38]
before experimental observation of dual-occupancy crystal
structures in complex with the A2AAR.
[39, 40] Conversely, the
X-ray structure of the N7-demethylated analogue theophyl-
line shows that this molecule adopts only one of these binding
modes, where the acidic hydrogen at position N7 makes an
additional H-bond contact with N2536.55 (Figure 3). We thus
evaluated whether our recently developed dual-topology
protocol QligFEP was suitable to capture this different
behavior, by a direct estimation of relative binding free
energies between the two poses, in analogy to the efficiency of
this protocol to compare topologically unrelated ligands (e.g.,
scaffold hopping).[6] The results for the A2A-xanthine system
shown in Table 3 show that this is the case: the negligible
calculated free energy difference between the two poses for
caffeine is in line with the equally populated dual binding
mode in the crystal structure with the A2AAR (PDB code
5MZP, Figure 3 A). In contrast, the single binding mode
observed in the crystal structure of theophylline (blue color in
Figure 3A) is energetically favored by 1.6 kcal mol@1. Subse-
quent application of the same strategy in the generated
chromone series showed a similar energy gap between the two
binding poses considered for the simplest chromone in our
series (4a, Figure 3 B), with pose A being 1.7 kcal mol@1 more
favorable than pose B. Notably, this energy gap increases
significantly for the highest affinity compound 4 d, suggestive
Table 2: SPR affinity data for the series of Chromone derivatives
synthesized in this work.
Compound Substituents pKD
[a]
R2 R5 R6 R7
4a[b] H H H H 5.95
4b[b] H H C3H7 H 6.20
4c H CH3 H H 5.80
4d[b] (Chromone 14) H H C3H7 COCH3 8.60
5a[b] CH3 H H H 5.10
5b CH3 H C3H7 H 5.42
5c CH3 CH3 H H 5.36
5d CH3 H C3H7 COCH3 5.90
8a H H H H 5.50
8b H H H C3H7 5.70
8d H H COCH3 C3H7 5.90
[a] Experimental errors in all cases reported as approximately 0.1 pKD
unit, that is, less than 0.1 kcal mol@1. [b] Compounds previously reported
in ref. [30]. Figure 3. A) Dual binding mode of caffeine, as extracted from the
A2AAR crystal structure with the A2AAR (PDB code 5MZP). Colour code
is green (binding mode A) and magenta (binding mode B). B) mod-
elled binding modes of Chromone 4a, following the same colouring
Scheme as in panel A.
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of an optimal anchoring of the R6 acetate and R7 n-propyl
substituents in pose A (Table 3).
We consequently retained the selected binding pose for
each scaffold (i.e., xanthine and chromone) and computed the
affinity shifts observed upon methylation. The calculations
reproduced the experimental decrease in affinity observed for
caffeine, as compared to the N7 demethylated analogue
theophylline (Table 3). Similarly, the corresponding FEP
calculations capture the experimentally observed negative
effect on A2A affinity due to methylation on R
2 in the original
chromones series 4 (see series 5, see Table 2).[30] The two pair
comparisons performed (4a ! 5a and 4d ! 5d, see Table 3)
qualitatively capture this effect, which is experimentally more
pronounced in the last case. Notably, a comparison of the
endpoint configurations of the 4d ! 5d FEP transformation
provide the structural reason of this effect: to avoid the
induced steric hindrance of the new methyl group with
Asn2536.55, the core scaffold of 5 d moved approximately 1.5 c
away from the original pose A of 4 d while maintaining the
interaction between the nitrogen in the 4-methylthiazole
group and the key asparagine residue.
X-Ray Crystallography
In an effort to unequivocally reveal the binding mode of
the chromone scaffold, the A2AAR-STAR2 construct
[27] was
crystallized with compound 4d (PDB code: 6ZDR) and its 2-
methyl analogue 5d (PDB code: 6ZDV). The structures were
obtained following the in meso soaking approach (see
Supporting Information, Methods), and could be refined
down to a resolution of 1.92 and 2.13 c respectively. Statistics
for data collection and refinement are given in the Supporting
Information, Table S2. The overall structure of the A2AAR
receptor is highly similar to previously solved structures with
other antagonists (see Figure 4A), with an RMSD of 0.46 c
for the Ca trace as compared to the ZM241385 structure
(PDB 4EIY, calculated using PyMOL[42]). The two structures
show clear positive omit density at 1s for the presence of the
chromone compounds in the orthosteric binding site (Fig-
ure 4B and C), in both cases adopting binding mode A
(Figure 4D and E). All residues in the binding site show
a conserved rotameric state between the two structures and
the A2AAR-ZM241385 complex. The only exception is
Y2717.36, which slightly rotates outward served to accommo-
date the alkyl tail of the chromone at R6 (see Supporting
Information, Figure S2A), an induced-fit effect that was
previously observed for other A2AAR ligands.
[33] The struc-
ture with the high affinity ligand 4 d shows outstanding
agreement with the computational model (see Figure 5A)
with an RMSD of 0.67 c between the docked and exper-
imental poses, and is indeed highly similar to previously
reported binding modes of the compound.[30,32] The core of
the scaffold is anchored by an H-bond between the nitrogen
in the 4-methylthiazole ring (coplanar with the chromone
scaffold) and N2536.55, and complemented by a p-p stacking
with F168EL2, in line with the binding pattern observed for
many other A2AAR antagonists.
[20] The ester at position R7 is
stabilizing the Glu1695.30–His2647.29 ionic pair, which closes
the EL2-EL3 interface, while the propyl at R6 makes contacts
with Tyr2717.53 and Met2707.52. Given the good resolution of
the structure, we could observe a well-defined water network
of the interface between the carbonyl moiety of the chromone
core and the receptor (Figure 4D). While most water
positions are conserved as compared to the A2AAR-
ZM241385 complex, ligand 4d displaces a number of water
molecules observed in the first hydration shell around that
ligand (see Supporting Information, Figure 2B). Some of
these waters were previously associated to a high-energy or
“unhappy” state,[30] which could partially explain the high
affinity of this particular compound.
The A2AAR-5b complex (Figure 4E) further shows that
methylation at position R2 displaces the chromone core by
1.79 c, in accordance with observations from the FEP
simulations (Table 3 and Figure 5 B, RMSD = 1.24 c between
docked and experimental ligand configuration). The 4-
methylthiazole ring of compound 5d remains almost co-
planar with the chromone scaffold (torsional angle of 16
degrees), and the H-bond interaction between the nitrogen in
this ring and Asn2536.55 is maintained. Indeed, the methyl-
ation does not disrupt the position of Asn2536.55, which
remains linked to Glu1695.30 via a conserved water molecule.
Similarly, the water molecule deeper in the binding crevice
remains, mediating a common anchoring point between the
carbonyl group of the two ligands and His2767.43. However,
the relative displacement of the chromone core on 5d situates
the substituents at R6 and R7 in sub-optimal pockets (Fig-
ure 4D), displacing two of the water molecules described for
compound 4d, while a new water molecule in the 5d complex
replaces the role of the acetate in 4d (see Figure 5 D) in the
stabilization of the Glu1695.30–His2647.29 ionic pair. This could
explain why the inclusion of an acetyl moiety in compound 5d
could not recover the affinity of the parent 5 b (DpKD = 0.48,
Table 2) as much as it was observed for the 4b/4 d pair
Table 3: Calculated free energy difference between two alternative poses for A2AAR antagonists.
Pose comparison A ! B Ligand perturbation
Ligand 1 (H)! Ligand 2 (CH3)
Ligand 1 DDGcalc [kcalmol
@1] Ligand 2 DDGexp [kcalmol
@1] DDGcalc [kcalmol
@1][a]
Caffeine 0.47:0.49 – – –
Theophylline 1.59:0.87 Caffeine 0.6[b] 0.31:0.32
4a 1.65:0.93 5a 1.16:0.1[c] 2.06:0.72
4d 8.76:0.81 5d 3.68:0.1[d] 1.66:1.09
[a] Calculations performed in the selected pose A (see text). [b] DGbind (caffeine—theophylline), extracted from ChEMBL.
[41] [c] DGbind (5a–4a) and
[d] DGbind (5d–4d), data from Table 2.
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(DpKD = 2.6). Finally, the crystal structures offered the
opportunity to revise the 4d ! 5d FEP transformation,
which was somewhat underestimated (see Table 3). However,
the calculated value using the starting pose from the
experimental coordinates did not change significantly,
(DDGcalc = 1.54: 1.22 kcalmol@1) indicating that the docking
pose was an accurate enough starting point for the FEP
calculations.
Conclusion
We describe a robust workflow to iteratively improve
receptor-ligand binding models, based on mapping of avail-
able experimental data onto structural information via free
energy calculations. We applied this protocol to provide new
insights in the binding mode of a recent series of A2AAR
antagonists. An initial binding mode hypothesis was gener-
ated based on the exploration of BPM and SAR data of the
original chromone series using FEP. This constituted the basis
for the design, synthesis and evaluation of an expanded series
of chromone derivatives. The experimental results were
conveniently interpreted with the aid of a second iteration
of FEP calculations, which reinforced the binding hypothesis.
Finally, X-ray crystallography experimentally confirmed this
binding mode, supporting the rational design of these com-
pounds. These structures, combined with the FEP calcula-
tions, provide structural and energetic insights in the deter-
minants of high affinity binding of the chromone scaffold
series. We expect the presented workflow to be of general
applicability in structure-based drug design, particularly in
the case of GPCRs where structures of receptor-ligand
complexes are increasingly available.
Figure 4. A) Crystal structures of the A2AAR and compound 4d (PDB code: 6ZDR), ligand shown in sticks and sodium ion shown as a sphere.
Electron densities of chromones 4d (B) and 5d (C; PDB code: 6ZDV). Omit maps are 2Fo@Fc at 1 sigma (light blue mesh) and Fo-Fc at 3 sigma
(green mesh). Binding mode of compound 4d (D) and 5d (E); ligands and the conserved residue N2536.55 shown as sticks, water molecules in
red spheres.
Figure 5. Crystal structure (orange) and modelled coordinates (cyan)
of (A) the highest affinity compound 4d (PDB code: 6ZDR) and (B)
the methylated derivative 5d (PDB code: 6ZDV) with the A2AAR. H-
bond interactions are indicated in magenta.
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